An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Distribution, Metabolism and Excretion of [14C]-STX-478 Following Single-Dose Oral Administration
Latest Information Update: 16 Apr 2025
At a glance
- Drugs LY 4064809 (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Scorpion Therapeutics
- 11 Apr 2025 Status changed from not yet recruiting to recruiting.
- 01 Apr 2025 New trial record